IDH 305

Drug Profile

IDH 305

Alternative Names: IDH305

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours
  • Phase Unknown Glioma

Most Recent Events

  • 05 Dec 2016 University of Texas Southwestern Medical Center plans a phase II trial for Glioma (Neoadjuvant therapy, Inoperable/Unresectable) in USA (PO) (NCT02987010)
  • 29 Nov 2016 Novartis suspends recruitment in a phase I clinical trial in Acute myeloid leukaemia (First-line therapy) in Australia (PO) (NCT02826642)
  • 29 Nov 2016 Novartis suspends recruitment in a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, Australia, Belgium, Netherlands, Canada, Spain, Singapore and Germany (PO) (NCT02381886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top